Equity Research, Broker Reports, and media content on Basilea Pharmaceutica

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about Basilea Pharmaceutica
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on Basilea Pharmaceutica. We currently have 31 research reports from 3 professional analysts.

Open
N/A
Range Today
N/A
52 Week
6740/9540c
Daily Volume
N/A
# Shares
0m
Daily Liquidity
0.0%
Pension Liability
Enterprise Value
n/am
Market Cap
819.1m
Latest PE (hist)
Div Yield
Date Source Announcement
23Apr19 11:27 EQS Basilea Pharmaceutica AG (BSLN-CH): Derazantinib has potential in iCCA and beyond
28Feb19 12:05 EQS Basilea Pharmaceutica AG (BSLN-CH): Cresemba on track, pipeline expanding
25Jan19 15:18 EQS Basilea Pharmaceutica AG (BSLN-CH): Derazantinib to enter combo trial with Roche's Tecentriq
10Jan19 15:37 EQS Basilea Pharmaceutica AG (BSLN-CH): Derazantinib interim data in line with expectations
10Dec18 06:15 GNW Basilea Pharmaceutica AG : Continued strong Cresemba® (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea
14Nov18 06:15 GNW Basilea presents preclinical data on its anticancer drug candidate BAL101553 at EORTC-NCI-AACR symposium
17Aug18 09:15 EQS Basilea Pharmaceutica AG (BSLN-CH): Cresemba shines in H1/2018 results
  • Frequency of research reports

     

  • Research reports on

    Basilea Pharmaceutica

  • Providers covering

    Basilea Pharmaceutica